Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopaenia with thrombosis: A clinical outcome study

Thrombosis and Haemostasis

Volumn 86, Issue 5, 2001, Pages 1170-1175

  Chong, B H ^a   Gallus, A S ^a   Cade, J F ^a   Magnani, H ^a   Manoharan, A ^a   Oldmeadow, M ^a   Arthur, C ^a   Rickard, K ^a   Gallo, J ^a   Lloyd, J ^a   Seshadri, P ^a   Chesterman, C N ^a  

^a FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

Danaparoid; Dextran; Heparin induced thrombocytopaenia; Heparinoid; Thrombosis

Indexed keywords

ANTIBODY; BLOOD CLOTTING FACTOR 10A; DANAPAROID; DEXTRAN 70; HEPARIN; HEPARINOID; SEROTONIN; WARFARIN; CHONDROITIN SULFATE; DERMATAN SULFATE; DEXTRAN; HEPARAN SULFATE;

ADULT; AGED; ARTICLE; AUSTRALIA; BLEEDING; BOLUS INJECTION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; EMBOLISM; FEMALE; FLUSHING; HOSPITAL; HOSPITAL DISCHARGE; HUMAN; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEROTONIN RELEASE; STATISTICAL ANALYSIS; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; THROMBUS; TREATMENT OUTCOME; VOMITING; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; PHARMACOKINETICS; SURVIVAL RATE;

AGED; CHONDROITIN SULFATES; DERMATAN SULFATE; DEXTRANS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; HEPARIN; HEPARITIN SULFATE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL RATE; THERAPEUTIC EQUIVALENCY; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; WARFARIN;

EID: 0035167688     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1616046     Document Type: Article

References (24)

1. Clinical presentation of heparin-induced thrombocytopenia
2. Temporal aspects of heparin-induced thrombocytopenia
3. A 14-year study of heparin-induced thrombocytopenia
4. Heparin-induced thrombocytopaenia
5. Heparin-induced thrombocytopaenia - Association of thrombotic complications with a heparin-dependent IgG antibody which induces platelet aggregation, release, and thromboxane synthesis
6. Heparin-associated thrombocytopenia
7. Heparin-induced thrombocytopenia: Towards consensus
8. Pharmacokinetic considerations on Orgaran (Org 10172) therapy
9. Orgaran (Org 10172): Its pharmacological profile in experimental models
10. Danaparoid: A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia
11. Heparin-induced thrombocytopenia: Studies with a new low molecular weight heparinoid, Org 10172
12. Parenteral anticoagulation with the heparinoid Lomoparan (Org 10172) in patients with heparin induced thrombocytopenia and thrombosis
13. Heparin-induced thrombocytopenia Type II: Successful use of Orgaran (ORG 10172) in intensive care patients
14. Orgaran in heparin-induced thrombocytopenia
15. Orgaran (danaparoid sodium) use in the syndrome of heparin-induced thrombocytopenia
16. New treatment options for heparin-induced thrombocytopenia
17. Heparin-induced thrombocytopenia (HIT): An overview of 230 patients treated with orgaran (Org 10172)
18. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study
19. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia
20. Heparin-induced thrombocytopenia with thromboembolic complications: Meta-analysis of two prospective trials to assess the value of parenteral treatment with lepidurin and its therapeutic APTT range
21. Argatroban provides effective and safe anticoagulation in patients with heparin-induced thrombocytopenia: A prospective, historical controlled study
22. Prevention of venous thromboembolism
23. Annotation: Heparin-induced thrombocytopenia
24. Longitudinal data analysis for discrete and continuous outcomes